Can the new Alzheimer’s drug, Lecanemab, be effective enough?
10
Jan
Can the new Alzheimer’s drug, Lecanemab, be effective enough? Subject: International relations Context: The United States Food and Drug Administration (USFDA) has granted fast-track approval to an Alzheimer’s medicine which, initial results show, reduces the amyloid beta protein deposition in the brain – a classic symptom of the neurodegenerative disease. Two new drugs […]